ABP-745 for
Acute Gout
Market Opportunity
and Limitations of
Existing Therapies

ABP-745 for Acute Gout

ABP-745, an analog of colchicine, is a unique anti-inflammatory oral drug under Phase 2 trials for the relief and prevention of the pain and inflammation of acute gout flares, which are caused by the persistent chronic grout.

Sustained excessive serum uric acid (sUA) levels can lead to the deposition of monosodium urate (MSU) crystals in joints, particularly in lower extremities, triggering sudden excruciating pain and inflammation associated with acute gout [1].

In preclinical animal studies, ABP-745 showed great potency of inhibiting the release of multiple inflammatory cytokines, including IL-1β, IL-6, IL-18, and TNF-α, and suppressing activation of the NLRP3 inflammasome. ABP-745 addresses key limitations of colchicine, reducing toxicity by 25- to 30-fold, with no drug–drug interactions.

Two completed Phase 1 clinical trials showed ABP-745 was safe and well tolerated in healthy subjects. At a high dose, systemic exposure to ABP-745 in humans was nearly 100-fold higher than that achieved with colchicine at 0.6 mg, suggesting that higher doses of ABP-745 may provide more effective suppression of inflammation and pain.

Safety Profiles

In Phase 1 clinical trials comparing ABP-745 to colchicine, ABP-745 was safe and well tolerated. At a high dose, systemic exposure to ABP-745 in humans was nearly 100-fold higher than that achieved with colchicine at 0.6 mg, suggesting that higher doses of ABP-745 may provide more effective suppression of inflammation and pain. In addition,  ABP-745 remained safe and well tolerated at plasma concentrations exceeding 200 ng/mL, whereas significant toxic reactions were observed when plasma colchicine concentrations exceeded 5 ng/mL.

Market Opportunity and Limitations of Existing Therapies

According to Frost & Sullivan, the global population experiencing acute gout flares was 45.4 million in 2024 and is expected to reach 68.2 million by 2033. The U.S. has approximately 12 million patients with gout, with an average of approximately 6.6 acute gout flares per patient per year, corresponding to nearly 80 million acute gout flare episodes annually [2].

In 2021, the global market for therapies for acute gout flares was valued at $1.5 billion and approximately $1.6 billion in 2025. The market is subsequently expected to grow to $3.1 billion by 2030. In the U.S., the market for therapies for acute gout flares remained relatively stable at approximately $0.7 billion in both 2021 and 2025 and is expected to grow to $1.4 billion by 2030.

Approved therapies recommended by existing treatment guidelines, such as colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids, are associated with varying degrees of serious adverse effects.

References

  1. Dalbeth N, Gosling AL, Gaffo A, et al. Gout. Lancet. 2021 May 15;397(10287):1843-1855.
  2. Singh JA, Morlock A, Morlock R. Gout Flare Burden in the United States: A Multiyear Cross-Sectional Survey Study. ACR Open Rheumatol. 2025 Jan;7(1):e11759.